Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia

Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial – The Lancet Psychiatry (link to abstract – $ for full-text)

Commentaries: Drug Eases Tardive Dyskinesia Linked to Antipsychotic Use – Medscape (free registration required) AND Second Tardive Dyskinesia Drug Works – MedPage Today (free registration required)